Back to top
more

Catalent (CTLT)

(Delayed Data from NYSE)

$53.61 USD

53.61
1,680,704

+0.03 (0.06%)

Updated May 30, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review

by Zacks Equity Research

JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.

FibroGen (FGEN) DMD Drug Pamrevlumab Gets FDA's Fast Track Tag

by Zacks Equity Research

The FDA bestows a Fast Track designation to FibroGen's (FGEN) anti-CTGF antibody, pamrevlumab, to treat patients with Duchenne muscular dystrophy. Shares up.

Catalent (CTLT) Expands Deal With Moderna for COVID-19 Vaccine

by Zacks Equity Research

Catalent (CTLT) expands its collaboration with Moderna to provide a new high-speed vial filling line for the manufacture of the latter's COVID-19 vaccine.

United Therapeutics (UTHR) Gains on Tyvaso Label Expansion

by Zacks Equity Research

United Therapeutics' (UTHR) Tyvaso is now the only FDA-approval therapy for treating serious, life-threatening disease, pulmonary hypertension associated with interstitial lung disease.

Jazz's (JAZZ) Vyxeos Gets FDA Nod for Pediatric Leukemia

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) gets FDA approval for label expansion of its cancer drug, Vyxeos, in pediatric patients with newly-diagnosed therapy-related acute myeloid leukemia.

Time to Focus on Catalent (CTLT) for Strong Earnings Growth Potential

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

Translate (TBIO) Down on Unsatisfactory CF Drug Study Results

by Zacks Equity Research

Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.

Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

Catalent (CTLT) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Catalent (CTLT) has been struggling lately, but the selling pressure may be coming to an end soon

Spectrum's (SPPI) NSCLC Drug Gets FDA's Fast Track Designation

by Zacks Equity Research

The FDA grants a Fast Track designation to Spectrum Pharmaceuticals' (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.

USNA vs. CTLT: Which Stock Is the Better Value Option?

by Zacks Equity Research

USNA vs. CTLT: Which Stock Is the Better Value Option?

3 Reasons Why Growth Investors Shouldn't Overlook Catalent (CTLT)

by Zacks Equity Research

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Catalent (CTLT) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Catalent (CTLT) delivered earnings and revenue surprises of 12.50% and 1.66%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

by Zacks Equity Research

Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.

Catalent (CTLT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ayala Pharmaceuticals (AYLA) Soars: Stock Adds 13.2% in Session

by Zacks Equity Research

Ayala Pharmaceuticals (AYLA) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.

Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

by Zacks Equity Research

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.

Moderna (MRNA) COVID-19 Vaccine Gets Authorization in Europe

by Zacks Equity Research

Moderna (MRNA) gets conditional use authorization for coronavirus vaccine, mRNA-1273, for use in adults in EU member states.

Looking for a Growth Stock? 3 Reasons Why Catalent (CTLT) is a Solid Choice

by Zacks Equity Research

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Moderna (MRNA) Raises COVID-19 Vaccine Production Target

by Zacks Equity Research

Moderna (MRNA) raises lower end of its global manufacturing target for its coronavirus vaccine by 20% for 2021. The company still aims to deliver up to one billion doses in the year.

Heron Therapeutics (HRTX) Looks Good: Stock Adds 6.8% in Session

by Zacks Equity Research

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Aurinia (AUPH) Looks Good: Stock Adds 5.5% in Session

by Zacks Equity Research

Aurinia (AUPH) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Here's Why Catalent (CTLT) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.

JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising

by Zacks Equity Research

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.